Read our latest updates & insights

Biogen and Samsung Bioepis announce partnership for the commercialisation of biosimilar ranibizumab and aflibercept for major markets world side including the US, Canada, Europe, Japan and Australia. Biogen has also acquired exclusive commercialisation rights for its anti-T...

Alvotech and STADA announce agreement for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe. Under the agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, with STAD...

Alvotech announced that it has entered an exclusive strategic partnership with Stada Arzneimittel for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe.

Under the agreement Alvotech will be responsible for the ...

Henlius Biotech wins ‘Biosimilar Initiative of the Year’ for its biosimilar rituximab at the Global Generics and Biosimilars Awards.

Biogen and Samsung Bioepis announce partnership for the commercialisation of biosimilar ranibizumab and aflibercept for major markets world side including the US, Canada, Europe, Japan and Australia. Biogen has also acquired exclusive commercialisation rights for its anti-T...

Biogen and Samsung Bioepis announce partnership for the commercialisation of biosimilars ranibizumab and aflibercept. The agreement covers the US, Canada, Europe, Japan and Australia. Under the agreement, Biogen will make one $100M upfront payment, with up to $210M payable ...

FDA approves Sandoz’s pegfilgrastim biosimilar Ziextenzo®.

Gene Techno Science and Kishi Kasei announce agreement for the joint development of an aflibercept biosimilar.

Pfizer releases positive interim analysis of data from clinical trials of Pfizer’s Inflectra®.

AbbVie releases Third-Quarter results, showing an overall decrease in Humira® revenues of 3.7% due to biosimilar competition. While Humira® revenues continued to increase in the US by 9.6%, internationally revenues decreased by 33.5%.